Abstract submission

A big THANK YOU to all submitters for their contribution to EULAR 2018.
Contact in case of questions: eular.abs@mci-group.com

Important information: Please read carefully

General:

Abstracts can only be submitted online via the online abstract submission system.
Abstracts sent by post or email will not be accepted. No exceptions will be made.

Technical requirements:

The internet abstract submission system works best with Internet Explorer 8.0 or higher and Mozilla Firefox 5.0 or higher and Chrome 16 or higher.
Cookies and JavaScript need to be enabled.

Abstract submission must be in one of the three different categories:
a. Medical or Research Professional / Clinician
b. Health Professional in Rheumatology / Practice and Research
c. PARE Member / Patient

The categories are subdivided into topics (Abstract topics).
The correct category and topic must be selected to ensure correct scoring.
The content of the abstract must be topic related.

Splitting of data originating from the same study across several abstracts and/or
topics is not permitted and will lead to rejection of the abstracts.

For standardisation, the acceptable length of the abstract is not more than 3600 characters and 55 lines, authors’ details and headers included. This also includes non-visible characters such as spaces as well as punctuation.

The abstract should be structured into the following sections:
a. A title which clearly indicates the nature of the investigation
b. Background
c. Objectives
d. Methods
e. Results
f. Conclusions
g. References

Up to two tables can be included in the results section with the following criteria:
• Maximum number of columns: 12
• Maximum number of rows: 20
• If a second table is added the number of columns and rows decreases by the
number of columns/rows used in the first table

One graph/image can be included with the following criteria :

Image width

min. 50 pixels

max. 750 pixels

Image height

min. 50 pixels

max. 750 pixels

Image quality

min. 96 dpi

max. 300 dpi

Image file size

min. 40 KB

max. 1000 KB (1MB)

Allowed file type

gif, jpg

Abstracts can be saved in “Draft” status to be re-edited and modified until the submission deadline (31 January 2018, 23:59 CET).
Therefore, the submitter will be required to create a user account.

Abstracts fulfilling all criteria can be saved in “Final submission” status. Only abstracts in “Final submission” status will be regarded as successfully submitted and considered for the congress. Abstracts in “Final submission” status can be re-edited and modified until the submission deadline (31 January 2018, 23:59 CET).

An abstract can only be submitted if the “Rules and Regulations including the
EULAR Embargo Rules” on the online abstract form are read and accepted.

Conflict of interest: It is the intent of EULAR to provide highquality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during the abstracts submission.

The presenting author can be any of the listed authors, preferably without affiliations
to industry.

The inclusion of trade names/brand names is not allowed in the abstract. The mentioning of agents/molecules must follow the scientific standard for publications.

Abstracts accepted for the congress are subject to the “EULAR Embargo Rules” and the “Transfer of copyright” as published in the right column on this page. With the submission of an abstract the authors agree to the embargo rules and the transfer of copyright.

The corresponding author has the right to grant, and does grant on behalf of all authors an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and EULAR to publish the abstract (if accepted) in any media and to exploit all subsidiary rights.

Only abstracts that contain original data can be submitted.

Abstracts should not be submitted if the following applies:
a. The abstract contains data that has been published or accepted for publication in
a print or online journal
b. The abstract contains data that was presented at a scientific meeting more than
12 months prior to EULAR 2018

Abstracts containing data that has been presented or will be presented at a different scientific meeting during a 12 months period prior to EULAR 2018 can be submitted. This fact must be indicated on the submission form.

Abstracts having been submitted for publication or to a scientific meeting, but are pending acceptance, can be submitted without restrictions. However, once the abstract has been accepted by EULAR it is automatically subject to the EULAR embargo rules.

The reviewers will judge the abstracts according to the scientific or clinical value,
relevance to EULAR, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.

Please ensure that your abstract does not contain spelling, grammatical or scientific errors, as it will be reproduced exactly as submitted. No proofreading will be done.

Abstract acceptance will be in one of three categories: oral presentation, poster presentation, publication only.

Should the abstract be selected for oral presentation, the authors, represented by the presenting author will have to sign an agreement to grant EULAR the right to record the presentation (audio and slide) and subsequently use it for educational purposes (with or without a fee). The full text of the agreement can be found in the right column on this page.

Accepted abstracts will be published in a supplement to the Annals of Rheumatic Diseases. Information on accepted abstracts (title and authors) will also be available online on the EULAR Website about one month prior to the congress.
Published abstracts will be available in the EULAR Abstract Archive during and after the congress.

The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session and the time assigned by the EULAR Scientific Committee. We therefore recommend that submitters of abstracts register for the congress simultaneously with the abstract submission.

Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract. The final decision about acceptance of an abstract will be taken by the EULAR Scientific Committee.
EULAR does not correspond on the reasons for acceptance/rejection of an abstract.

If the presenting author needs to be changed, a request, indicating the listed
co-author who takes over the presentation, needs to be sent to MCI not later than
15 April 2018.

If you need to withdraw your abstract, a written statement reflecting the reasons for this decision must be sent to the EULAR Secretariat or MCI not later than
1 April 2018.

Instructions for abstract presentation

If an abstract is selected for oral presentation, the presenting author, as specified at submission, will be requested to present it in the assigned session.

Details will be communicated to the author by mid-April 2018.

If the abstract is selected for oral presentation, the authors, represented by the presenting author, will have to sign an agreement to grant EULAR the right to record the entire presentation (audio and slide) and subsequently use it for educational purposes (with or without a fee).

If an abstract is accepted as a poster presentation, the presenting author will be requested to be available for discussion during the corresponding poster viewing session.

Official language

Further information

About EULAR

The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavours to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.

Congress mission statement

The aim is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, in order to achieve progress in the clinical care of people with RMDs.